PURPOSE: Stromal cells in the tumor microenvironment, such as macrophages, play an active role in tumor growth and angiogenesis. However, little is known about relationships of biobehavioral factors with angiogenic cytokines and matrix metalloproteinases (MMP) produced by stromal cells. This study examined distress, MMPs, and angiogenic cytokines in ovarian cancer patients and in vitro. EXPERIMENTAL DESIGN: Patients suspected of ovarian cancer completed preoperative questionnaires. At surgery, 56 were confirmed to have epithelial ovarian cancer. Tumor samples were analyzed for macrophage (CD68(+)) and tumor cell levels of MMP-2, MMP-9, and vascular endothelial growth factor. In vitro stimulation of isolated macrophage cells by the stress hormones norepinephrine and cortisol was done to assess effects on MMP-9. RESULTS: Depressed patients showed significant elevations of MMP-9 in CD68(+) cells, adjusting for stage (P<0.0001). Patients with higher levels of current stress (P=0.01), life stress over the last 6 months (P=0.004), and general negative affect (P=0.007) also showed significantly greater MMP-9 in CD68(+) cells. In contrast, higher social support was associated with lower levels of MMP-9 (P=0.023) and vascular endothelial growth factor (P=0.036) in tumor cells. In vitro analyses showed that macrophage MMP-9 production could be directly enhanced (up to a 2-fold increase) by the stress hormones norepinephrine and cortisol. CONCLUSIONS: Ovarian cancer patients with elevated depressive symptoms, chronic stress, and low social support showed elevations in MMP-9 in tumor-associated macrophages. Direct in vitro enhancement of stromal MMP-9 production by stress hormones was also shown. These findings may have implications for patient outcomes in ovarian cancer.
PURPOSE: Stromal cells in the tumor microenvironment, such as macrophages, play an active role in tumor growth and angiogenesis. However, little is known about relationships of biobehavioral factors with angiogenic cytokines and matrix metalloproteinases (MMP) produced by stromal cells. This study examined distress, MMPs, and angiogenic cytokines in ovarian cancerpatients and in vitro. EXPERIMENTAL DESIGN:Patients suspected of ovarian cancer completed preoperative questionnaires. At surgery, 56 were confirmed to have epithelial ovarian cancer. Tumor samples were analyzed for macrophage (CD68(+)) and tumor cell levels of MMP-2, MMP-9, and vascular endothelial growth factor. In vitro stimulation of isolated macrophage cells by the stress hormones norepinephrine and cortisol was done to assess effects on MMP-9. RESULTS:Depressedpatients showed significant elevations of MMP-9 in CD68(+) cells, adjusting for stage (P<0.0001). Patients with higher levels of current stress (P=0.01), life stress over the last 6 months (P=0.004), and general negative affect (P=0.007) also showed significantly greater MMP-9 in CD68(+) cells. In contrast, higher social support was associated with lower levels of MMP-9 (P=0.023) and vascular endothelial growth factor (P=0.036) in tumor cells. In vitro analyses showed that macrophage MMP-9 production could be directly enhanced (up to a 2-fold increase) by the stress hormones norepinephrine and cortisol. CONCLUSIONS:Ovarian cancerpatients with elevated depressive symptoms, chronic stress, and low social support showed elevations in MMP-9 in tumor-associated macrophages. Direct in vitro enhancement of stromal MMP-9 production by stress hormones was also shown. These findings may have implications for patient outcomes in ovarian cancer.
Authors: G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan Journal: Nat Cell Biol Date: 2000-10 Impact factor: 28.824
Authors: Brent T Mausbach; Joel E Dimsdale; Michael G Ziegler; Paul J Mills; Sonia Ancoli-Israel; Thomas L Patterson; Igor Grant Journal: Psychosom Med Date: 2005 Jul-Aug Impact factor: 4.312
Authors: Susan K Lutgendorf; Erica L Johnsen; Brian Cooper; Barrie Anderson; Joel I Sorosky; Richard E Buller; Anil K Sood Journal: Cancer Date: 2002-08-15 Impact factor: 6.860
Authors: Eric V Yang; Cynthia M Bane; Robert C MacCallum; Janice K Kiecolt-Glaser; William B Malarkey; Ronald Glaser Journal: J Neuroimmunol Date: 2002-12 Impact factor: 3.478
Authors: Devika R Jutagir; Bonnie B Blomberg; Charles S Carver; Suzanne C Lechner; Kiara R Timpano; Laura C Bouchard; Lisa M Gudenkauf; Jamie M Jacobs; Alain Diaz; Susan K Lutgendorf; Steve W Cole; Aaron S Heller; Michael H Antoni Journal: Breast Cancer Res Treat Date: 2017-05-30 Impact factor: 4.872
Authors: Eileen H Shinn; Daniel J Lenihan; Diana L Urbauer; Karen M Basen-Engquist; Alan Valentine; Laura Palmero; Myrshia L Woods; Pooja Patel; Alpa M Nick; Mian M K Shahzad; Rebecca L Stone; Antoinette Golden; Emma Atkinson; Susan K Lutgendorf; Anil K Sood Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-09-17 Impact factor: 4.254
Authors: Susan K Lutgendorf; Premal H Thaker; Jesusa M Arevalo; Michael J Goodheart; George M Slavich; Anil K Sood; Steve W Cole Journal: Cancer Date: 2017-11-07 Impact factor: 6.860